Developer docs
API playgroundTry for free, no card

Search company profiles

GlycoMimetics

Full company profile

uuid00043hy

Namestring
GlycoMimetics
Legal namestring
Crescent Biopharma, Inc.
Company typeenum
Private
Founded yearint
2024
Descriptiontext

GlycoMimetics is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Gaithersburg, Maryland, that discovers and develops small-molecule glycomimetic therapeutics for oncology. The company's scientific premise centers on modulating carbohydrate-mediated biological interactions — particularly selectin-ligand binding implicated in tumor cell adhesion, metastasis and vascular biology — using chemically engineered sugar mimetics designed to improve drug-like properties relative to native glycans. Its pipeline has historically been oriented toward hematologic malignancies (notably uproleselan for acute myeloid leukemia) and has subsequently expanded into solid tumor indications.

The company operated as a publicly traded entity on NASDAQ under ticker GLYC and funded its development programs through repeated equity financings, accumulating more than $338M in capital across its independent history. It was pre-revenue throughout this period, with no approved products and economics driven entirely by R&D spend financed by capital markets rather than commercial sales. Scientific leadership was anchored by co-founder John Magnani, who served concurrently as VP, Chief Scientific Officer and SVP of Research, providing continuity of the carbohydrate-mimetic discovery platform. Headcount was small (11–50 employees), consistent with a focused clinical-stage biotech rather than a commercial-stage organization.

In October 2024, GlycoMimetics was acquired by Crescent Biopharma, and the combined entity now operates under the Crescent Biopharma name. The merger was supported by a $185M private placement by Crescent that extended the combined company's projected cash runway into 2028. As a result, GlycoMimetics no longer exists as an independent operating company, and its commercial destiny — including any future product launches — is determined within the Crescent Biopharma corporate structure.

Short descriptiontext

GlycoMimetics is a clinical-stage biopharmaceutical company founded in 2003 in Gaithersburg, Maryland, developing small-molecule glycomimetic therapeutics for cancer. Pre-revenue and acquired by Crescent Biopharma in October 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, cancer drug development, clinical stage biopharmaceutical, oncology drug discovery, glycomimetic therapeutics
Industry2 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles2 records
Revenue model1 record
1Pre-revenue biopharmaceutical
TypeSubscription Recurring
Description

As a clinical-stage biotech company prior to acquisition, GlycoMimetics was focused on developing therapies rather than generating revenue. The company was acquired by Crescent Biopharma in October 2024.

globenewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GlycoMimetics was a clinical-stage biopharmaceutical company that designed and developed small molecule therapeutics to treat various cancers, with a primary focus on solid tumor therapies. As a pre-revenue biotech, the company's core activity was advancing a proprietary pipeline of novel oncology drug candidates through research and clinical development, rather than commercial sales of approved products. The company's assets were acquired by Crescent Biopharma in October 2024.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Solid tumor oncology pipeline (clinical-stage)
CategoryBiopharmaceutical Therapeutics
Description

A pre-revenue, clinical-stage pipeline of small molecule therapeutics developed by GlycoMimetics to treat various cancers with a focus on solid tumors, intended for cancer patients and acquired by Crescent Biopharma in October 2024 for further development.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Crescent Biopharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

In October 2024, Crescent Biopharma entered into an acquisition agreement with GlycoMimetics, Inc. The transaction resulted in GlycoMimetics operating under the Crescent name following the close. This strategic acquisition was designed to combine GlycoMimetics' pipeline with Crescent's existing programs to develop therapies for solid tumors.

globenewswire.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing next-generation ADCs, including a leading PD-L1 ADC (Rina-S) that directly competes with Crescent's CR-002. ProfoundBio shares the same oncology ADC modality and target class focus.

TypeDirect peer
Description

Clinical-stage biotech developing ADCs with proprietary platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Comparable stage and ADC modality focus with differentiated linker/payload technology.

TypeDirect peer
Description

Clinical-stage oncology company developing a pipeline of ADCs and immuno-oncology therapeutics. Comparable in stage (clinical), modality (ADCs), and focus on solid tumors with differentiated targets, overlapping Crescent's CR-002 and CR-003 strategy.

TypeDirect peer
Description

Chinese biotech and originator of ivonescimab (PD-1xVEGF bispecific). Akeso is the developer of the same bispecific technology class that Crescent's CR-001 targets, making them the original innovator and most scientifically comparable peer in this emerging IO modality.

TypeDirect peer
Description

Clinical-stage precision oncology biotech developing small molecule therapies against novel allosteric targets. Comparable as a similarly sized, publicly listed oncology biotech with multiple clinical-stage assets and a similar R&D-heavy burn profile.

TypeDirect peer
Description

Clinical-stage oncology biotech developing INDUKINE conditionally activated therapeutics for solid tumors. Comparable as a similarly sized, venture-backed oncology biotech with a differentiated platform approach and clinical-stage assets.

TypeDirect peer
Description

Clinical-stage oncology biotech with a pipeline that includes bispecific antibodies and ADCs. Comparable in stage, modality mix (bispecifics + ADCs), and oncology focus, with similar investor profile and clinical development posture.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing immune-stimulating ADCs with proprietary linker technology. Directly comparable as an ADC-focused oncology biotech of similar stage and capital profile to Crescent Biopharma.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapies targeting the RAS/MAPK pathway. Comparable as a venture-backed clinical-stage oncology biotech with multiple programs and similar capital profile.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing ivonescimab, a PD-1xVEGF bispecific antibody, in-licensed from Akeso. Summit is the most direct competitor to Crescent Biopharma's CR-001, both targeting the same PD-1xVEGF mechanism for solid tumors with significant overlap in lead indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GlycoMimetics

Biopharmaceutical Therapeuticsglycomimetics.com

GlycoMimetics is a clinical-stage biopharmaceutical company founded in 2003 in Gaithersburg, Maryland, developing small-molecule glycomimetic therapeutics for cancer. Pre-revenue and acquired by Crescent Biopharma in October 2024.

What GlycoMimetics does

GlycoMimetics is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Gaithersburg, Maryland, that discovers and develops small-molecule glycomimetic therapeutics for oncology. The company's scientific premise centers on modulating carbohydrate-mediated biological interactions — particularly selectin-ligand binding implicated in tumor cell adhesion, metastasis and vascular biology — using chemically engineered sugar mimetics designed to improve drug-like properties relative to native glycans. Its pipeline has historically been oriented toward hematologic malignancies (notably uproleselan for acute myeloid leukemia) and has subsequently expanded into solid tumor indications.

The company operated as a publicly traded entity on NASDAQ under ticker GLYC and funded its development programs through repeated equity financings, accumulating more than $338M in capital across its independent history. It was pre-revenue throughout this period, with no approved products and economics driven entirely by R&D spend financed by capital markets rather than commercial sales. Scientific leadership was anchored by co-founder John Magnani, who served concurrently as VP, Chief Scientific Officer and SVP of Research, providing continuity of the carbohydrate-mimetic discovery platform. Headcount was small (11–50 employees), consistent with a focused clinical-stage biotech rather than a commercial-stage organization.

In October 2024, GlycoMimetics was acquired by Crescent Biopharma, and the combined entity now operates under the Crescent Biopharma name. The merger was supported by a $185M private placement by Crescent that extended the combined company's projected cash runway into 2028. As a result, GlycoMimetics no longer exists as an independent operating company, and its commercial destiny — including any future product launches — is determined within the Crescent Biopharma corporate structure.

GlycoMimetics firmographics

Firmographics
Name
GlycoMimetics
Legal name
Crescent Biopharma, Inc.
Website
https://glycomimetics.com
Company type
Private
Founded year
2024
Operating status
Acquired
Headcount range
11–50 employees
Short description
GlycoMimetics is a clinical-stage biopharmaceutical company founded in 2003 in Gaithersburg, Maryland, developing small-molecule glycomimetic therapeutics for cancer. Pre-revenue and acquired by Crescent Biopharma in October 2024.
Ownership category
akta.pro rank

GlycoMimetics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Small molecule therapeutics
  • Cancer drug development
  • Clinical stage biopharmaceutical
  • Oncology drug discovery
  • Glycomimetic therapeutics

Where GlycoMimetics is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GlycoMimetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pre-revenue biopharmaceutical: As a clinical-stage biotech company prior to acquisition, GlycoMimetics was focused on developing therapies rather than generating revenue. The company was acquired by Crescent Biopharma in October 2024.

Marketing channels1 record

GlycoMimetics product offering

Product offering

Core offering

GlycoMimetics was a clinical-stage biopharmaceutical company that designed and developed small molecule therapeutics to treat various cancers, with a primary focus on solid tumor therapies. As a pre-revenue biotech, the company's core activity was advancing a proprietary pipeline of novel oncology drug candidates through research and clinical development, rather than commercial sales of approved products. The company's assets were acquired by Crescent Biopharma in October 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • Solid tumor oncology pipeline (clinical-stage) A pre-revenue, clinical-stage pipeline of small molecule therapeutics developed by GlycoMimetics to treat various cancers with a focus on solid tumors, intended for cancer patients and acquired by Crescent Biopharma in October 2024 for further development.

Companies that use GlycoMimetics

Customer profile

Segments1 record

Ideal customer profiles2 records

GlycoMimetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

GlycoMimetics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Crescent BiopharmacoreStrategic or Co-development Partner · 1 October 2024In October 2024, Crescent Biopharma entered into an acquisition agreement with GlycoMimetics, Inc. The transaction resulted in GlycoMimetics operating under the Crescent name following the close. This strategic acquisition was designed to combine GlycoMimetics' pipeline with Crescent's existing programs to develop therapies for solid tumors.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

GlycoMimetics competitors and assessment

Company assessment

Direct peers

  • ProfoundBio: Clinical-stage biotech developing next-generation ADCs, including a leading PD-L1 ADC (Rina-S) that directly competes with Crescent's CR-002. ProfoundBio shares the same oncology ADC modality and target class focus.
  • Mersana Therapeutics: Clinical-stage biotech developing ADCs with proprietary platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Comparable stage and ADC modality focus with differentiated linker/payload technology.
  • Pyxis Oncology: Clinical-stage oncology company developing a pipeline of ADCs and immuno-oncology therapeutics. Comparable in stage (clinical), modality (ADCs), and focus on solid tumors with differentiated targets, overlapping Crescent's CR-002 and CR-003 strategy.
  • Akeso, Inc. Chinese biotech and originator of ivonescimab (PD-1xVEGF bispecific). Akeso is the developer of the same bispecific technology class that Crescent's CR-001 targets, making them the original innovator and most scientifically comparable peer in this emerging IO modality.
  • Black Diamond Therapeutics: Clinical-stage precision oncology biotech developing small molecule therapies against novel allosteric targets. Comparable as a similarly sized, publicly listed oncology biotech with multiple clinical-stage assets and a similar R&D-heavy burn profile.
  • Werewolf Therapeutics: Clinical-stage oncology biotech developing INDUKINE conditionally activated therapeutics for solid tumors. Comparable as a similarly sized, venture-backed oncology biotech with a differentiated platform approach and clinical-stage assets.
  • Compass Therapeutics: Clinical-stage oncology biotech with a pipeline that includes bispecific antibodies and ADCs. Comparable in stage, modality mix (bispecifics + ADCs), and oncology focus, with similar investor profile and clinical development posture.
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating ADCs with proprietary linker technology. Directly comparable as an ADC-focused oncology biotech of similar stage and capital profile to Crescent Biopharma.
  • Erasca, Inc. Clinical-stage precision oncology company developing small molecule therapies targeting the RAS/MAPK pathway. Comparable as a venture-backed clinical-stage oncology biotech with multiple programs and similar capital profile.
  • Summit Therapeutics: Clinical-stage biopharmaceutical company developing ivonescimab, a PD-1xVEGF bispecific antibody, in-licensed from Akeso. Summit is the most direct competitor to Crescent Biopharma's CR-001, both targeting the same PD-1xVEGF mechanism for solid tumors with significant overlap in lead indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

GlycoMimetics social profiles

Digital presence

GlycoMimetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GlycoMimetics leadership team

Management profile

Number of profiles

Profiles12 records

GlycoMimetics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GlycoMimetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlycoMimetics

What does GlycoMimetics do?

GlycoMimetics was a clinical-stage biopharmaceutical company that designed and developed small molecule therapeutics to treat various cancers, with a primary focus on solid tumor therapies. As a pre-revenue biotech, the company's core activity was advancing a proprietary pipeline of novel oncology drug candidates through research and clinical development, rather than commercial sales of approved products. The company's assets were acquired by Crescent Biopharma in October 2024.

Is GlycoMimetics a public or private company?

GlycoMimetics is a private company. It is classified as corporate owned and is currently acquired.

When was GlycoMimetics founded?

GlycoMimetics was founded in 2024. It employs 11 to 50 people.

Where is GlycoMimetics based?

GlycoMimetics is headquartered in Rockville, United States, in the North America region.

How does GlycoMimetics make money?

One revenue line is on record: pre-revenue biopharmaceutical.

Who are GlycoMimetics's main competitors?

Direct peers on record are ProfoundBio, Mersana Therapeutics, Pyxis Oncology, Akeso, Inc., Black Diamond Therapeutics, Werewolf Therapeutics, Compass Therapeutics, Bolt Biotherapeutics, Erasca, Inc. and Summit Therapeutics.

Does GlycoMimetics have an API?

No public API is recorded for GlycoMimetics.

What industry is GlycoMimetics in?

GlycoMimetics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesGlycobiology Market to Reach USD 732.05M by 2032 at 14.3% CAGR – PR TimesPW Consulting released a strategic market preview for the Glycomics/Glycobiology sector, projecting the market will grow from approximately USD 290 million in 2025 to USD 732.05 million by 2032, representing a 14.3% compound annual growth rate. The report identifies first-mover advantages before mid-2027, noting market concentration with the top three players capturing ~55% share and top five ~65%, while highlighting consolidation activity including Crescent Biopharma's 2025 merger with GlycoMimetics. The preview outlines strategic imperatives for 2026 planning, including prioritizing modular partnerships, investing in enzyme ecosystems, designing regulatory-first programs, and hedging with platform diversification to capture near-term product revenue and longer-term pipeline value.GlobeNewswireCrescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 MillionCrescent Biopharma completed its merger with GlycoMimetics, with shares trading on Nasdaq under CBIO. The company raised $200 million in gross proceeds, including $37.5 million in convertible notes, to support operations through 2027. It plans to submit an IND for CR-001 in Q4 2025 and report proof-of-concept data in H2 2026.GlobeNewswireCrescent Biopharma to Present at the TD Cowen 45th Annual Health Care ConferenceCrescent Biopharma will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 9:10 am ET. The company acquired GlycoMimetics in October 2024, and the combined entity will operate under the Crescent name. A live webcast and archived recording will be available.YahooGlycoMimetics Announces Merger with Crescent BiopharmaGlycoMimetics announced a merger with Crescent Biopharma, structured as a tax-free reorganization. Crescent shareholders will own a majority of the combined entity, with a $200 million private placement to support growth. The deal is expected to close in mid-2025 pending conditions and shareholder approvals.BenzingaGlycoMimetics Shares Are Soaring Tuesday: Here's WhyGlycoMimetics, Inc. announced a merger agreement with privately held biotech firm Crescent Biopharma, creating a combined company that will operate under the Crescent Biopharma name and focus on advancing solid tumor therapies. The company also secured $200 million in funding from investors to support operations through 2027 and further develop its lead therapeutic candidates CR-001, CR-002, and CR-003. The merger is expected to close in Q2 2025, with pre-acquisition GlycoMimetics stockholders holding approximately 3.1% of the combined entity while Crescent stockholders will own roughly 96.9%.BenzingaNasdaq Surges Over 100 Points; Pfizer Earnings Top Views - Pfizer (NYSE:PFE)Pfizer Inc. reported better-than-expected third-quarter results with adjusted EPS of $1.06, reversing from a loss of 17 cents a year ago, and revenue of $17.70 billion representing a 31% year-over-year increase that beat consensus estimates of $14.95 billion. U.S. markets showed mixed performance on Tuesday, with the Nasdaq Composite rising 0.74% to 18,704.19 while the Dow dipped 0.07%. The article also highlights several other market movers including GlycoMimetics surging 161% on a merger announcement and GeneDx gaining 47% after raising its full-year revenue guidance.Business InsiderGlycoMimetics enters acquisition agreement with Crescent BiopharmaGlycoMimetics entered an acquisition agreement with Crescent Biopharma, with a syndicate led by Fairmount and others committing $200M to purchase GlycoMimetics stock and warrants. The deal is expected to close in Q2 2025, with the combined company named Crescent Biopharma. GlycoMimetics' stockholders will own about 3.1% of the combined company.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of ShareholdersHalper Sadeh LLC, an investor rights law firm, announced investigations into Profire Energy, Inc. regarding its pending sale to CECO Environmental Corp. for $2.55 per share in cash, and into GlycoMimetics, Inc. regarding its proposed merger with Crescent Biopharma, Inc.BenzingaWhy GlycoMimetics Stock is Trading Higher MondayGlycoMimetics stock is trading 20% higher at 32 cents on Monday after Chief Medical Officer Edwin Rock disclosed the purchase of 305,000 shares at an average price of 26 cents per share via a Form 4 filing. The insider purchase was executed just before the stock move, representing approximately $79,300 in total value. The article attributes the share price appreciation directly to the insider buying activity, though it contains standard investor education content unrelated to the core news.